RT Journal
A1 Kuehn BM
T1 DUal-binding antibody
JF JAMA
JO JAMA
YR 2009
FD May 6
VO 301
IS 17
SP 1758
OP 1758
DO 10.1001/jama.2009.568
UL http://dx.doi.org/10.1001/jama.2009.568
AB 
The researchers isolated a variant of the monoclonal antibody biologic trastuzumab, which binds to the human epidermal growth factor receptor 2 (HER2); this variant also can bind vascular endothelial growth factor (VEGF) (Bostrum J et al. Science. 2009;323[5921]:1610-1614). The scientists visualized the structure of this 2-protein–binding variant using x-ray crystallography. Additionally, they found that a trastuzumab variant with high affinity for both HER2 and VEGF can inhibit cell proliferation mediated by these 2 proteins in a human cell line and inhibit tumor progression mediated by these proteins in a mouse model.